id stringlengths 32 32 | url stringlengths 31 1.58k | title stringlengths 0 1.02k | contents stringlengths 92 1.17M |
|---|---|---|---|
bad3d9a9196613ce6445313d77122a38 | https://www.forbes.com/sites/matthewherper/2011/06/12/scientists-create-a-living-laser/ | Scientists Create A Living Laser | Scientists Create A Living Laser
One of the first stories I was ever really proud of was on the history of green fluorescent protein, or GFP, a glowing protein found in jellyfish that can be used to make living things glow. I wasn't that surprised when GFP won the Nobel Prize a few years back. But this -- wow. Research... |
c808feeceaa72721be1a1da377a88936 | https://www.forbes.com/sites/matthewherper/2011/06/28/medical-journal-slams-medtronic-over-payments-to-doctors/ | Medical Journal Slams Medtronic Over Payments To Doctors | Medical Journal Slams Medtronic Over Payments To Doctors
A major medical journal has taken the dramatic step of publishing a series of articles alleging that side effects were downplayed or omitted in scientific articles about a Medtronic product used in spine surgery.
Instead, authors repeatedly asserted the device, c... |
f1198931448ae2149516dba9519e9cd5 | https://www.forbes.com/sites/matthewherper/2011/07/21/how-generics-and-obamacare-led-to-express-scripts-mammoth-purchase-of-medco/ | How Generics And ObamaCare Led To Express Scripts' Mammoth Purchase Of Medco | How Generics And ObamaCare Led To Express Scripts' Mammoth Purchase Of Medco
This morning, Express Scripts announced plans to buy rival Medco Health Solutions for $29 billion in cash and stock in a merger that will combine two of the largest managers of prescription drugs in the United States. It is the second-biggest ... |
ec902f392c5773a0fa696c3a7b29764d | https://www.forbes.com/sites/matthewherper/2011/08/03/rallying-pharmas-rebels/ | Rallying Pharma's Rebels | Rallying Pharma's Rebels
Bernard Munos
From the 08.22.11 issue of Forbes Magazine: Bernard Munos has a radical idea to save the drug industry: Take bigger risks and cut R&D.
It’s no secret that the pharmaceutical industry is suffering. With too few breakthroughs and stagnant finances, the stocks of some of the industry... |
fdfad85f5aef98addc38d554a2ce8e68 | https://www.forbes.com/sites/matthewherper/2011/12/29/five-predictions-for-biotech-and-medicine-in-2012/ | Five Predictions For Biotech And Medicine In 2012 | Five Predictions For Biotech And Medicine In 2012
Image via Wikipedia
Continuing a proud Forbes tradition, here is what I see happening as we move forward through 2012.
1. We'll see more super-expensive drugs. Charging $100,000, $200,000, or even $500,000 per patient per year is the most successful strategy in the drug... |
541eeacd277babaa7c6516f0d3a0c1d3 | https://www.forbes.com/sites/matthewherper/2012/02/09/the-best-drug-companies-of-the-past-15-years/ | The Best Drug Companies Of The Past 15 Years | The Best Drug Companies Of The Past 15 Years
Last summer, after writing a profile of Bernard Munos, who has made it his calling to understand what goes into pharmaceutical innovation, I posted two very simple tables based on Munos' data: of the drug companies that had approved the most drugs over the past decade, and o... |
12c439d50f24116758709829f88e05a7 | https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/ | The Truly Staggering Cost Of Inventing New Drugs | The Truly Staggering Cost Of Inventing New Drugs
Image by AFP/Getty Images via @daylife
During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company's corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl... |
1863cf0531ebd1a2d69d598abd88fde8 | https://www.forbes.com/sites/matthewherper/2012/03/28/the-drug-industrys-blind-alley/ | The Drug Industry's Blind Alley | The Drug Industry's Blind Alley
Jack Scannell, an analyst at Sanford C. Bernstein who covers European pharma, is becoming a must read for anyone trying to figure out what has gone wrong with the drug industry's innovation engine. His latest note to clients is a prime example: a damning look at how the drug industry tri... |
77fd5ffa9ac578bd77c9aa574abb9dd1 | https://www.forbes.com/sites/matthewherper/2012/05/01/jim-watson-who-discovered-dnas-structure-picks-his-favorite-gene/ | DNA Discoverer Jim Watson Picks His Favorite Gene | DNA Discoverer Jim Watson Picks His Favorite Gene
Nobel laureate Dr. James D. Watson (Photo credit: Wikipedia)
In Forbes' "Love Only One" feature, which is returning after a long hiatus, we ask the biggest luminaries in different fields for their top picks in everything from stocks to gadgets. Here, we ask Nobel laurea... |
f16952e147e209f15d73c21da0334a28 | https://www.forbes.com/sites/matthewherper/2012/05/07/a-fathers-battle-to-change-the-future-of-brain-research/ | A Father's Battle To Change The Future Of Brain Research | A Father's Battle To Change The Future Of Brain Research
This story appears in the May 2012 issue of ForbesLife under the headline "Brain Trust."
Garen and Shari Staglin. Photograph by Eric Millette
At a recent lunch organized by Jeffrey Lieberman, Columbia University’s chairman of psychiatry, New York’s top neurologic... |
5f739917519a429aab35bb88e2813733 | https://www.forbes.com/sites/matthewherper/2012/12/27/the-most-important-new-drug-of-2012/?partner=yahootix | The Most Important New Drug Of 2012 | The Most Important New Drug Of 2012
The Food and Drug Administration looks set for a great 2012; with a few days left to go, it has approved 40 new drugs and vaccines, one of the most impressive totals ever, according to data from Pharmaceutical Approvals Monthly and FDA press releases. In this haul, one medicine stand... |
7253f88bb7afe53d2ed5dab8416b0fa0 | https://www.forbes.com/sites/matthewherper/2013/02/05/forbes-healthcare-summit-using-big-data-to-make-patients-better/ | Forbes Healthcare Summit: Using Big Data To Make Patients Better | Forbes Healthcare Summit: Using Big Data To Make Patients Better
This is one of a series of posts that presents, nearly in its entirety, the first annual Forbes Healthcare Summit that was held on December 5, 2012, in the Allen Room at Jazz at Lincoln Center in Manhattan. Two hundred and thirty-two executives, entrepren... |
093cb8554ed9de1bdaf40bf3df8aaa10 | https://www.forbes.com/sites/matthewherper/2013/02/06/biogen-to-buy-elans-tysabri-rights-for-3-25-billion/ | In Wise Move, Biogen Spends $3.25 Billion For Rest Of Tysabri. Now What Happens To Elan? | In Wise Move, Biogen Spends $3.25 Billion For Rest Of Tysabri. Now What Happens To Elan?
Biogen Idec will purchase all rights to the blockbuster multiple sclerosis drug Tysabri from its partner, Elan Pharmaceuticals, for $3.25 billion, adding a capstone to a long and tangled journey for a drug that was once withdrawn f... |
6476861f403d3c9cdec73e8ed01b366a | https://www.forbes.com/sites/matthewherper/2013/02/08/more-polio-workers-killed/ | More Polio Workers Killed | More Polio Workers Killed
This is a global tragedy. There are others to blame aside from the militants in Kano. The U.S. government carries blame for using a ruse including flu vaccines to try and catch Osama Bin Laden. Perhaps Pfizer's experiments with Trovan in Nigeria, which became controversial, have helped poison ... |
2e349c50abcb566037e8f848ec98fa2f | https://www.forbes.com/sites/matthewherper/2013/02/19/a-graphic-that-drives-home-how-vaccines-have-changed-our-world/ | How Vaccines Have Changed Our World In One Graphic | How Vaccines Have Changed Our World In One Graphic
The data in this graphic come from the web site of the Centers for Disease Control & Prevention, but a graphic designer in Purchase, N.Y., named Leon Farrant has created a graphic that drives home what the data mean.
Below is a look at the past morbidity (how many peop... |
53f786c347f456102bbeacf039c54e31 | https://www.forbes.com/sites/matthewherper/2013/02/27/how-a-creative-biotech-vc-exit-looks-in-2013/ | What A Creative Biotech VC Exit Looks Like In 2013 | What A Creative Biotech VC Exit Looks Like In 2013
The lack of a strong IPO market makes life tougher for biotech venture capitalists. Boston's Third Rock Ventures has done some creative deals to try to get a return. Details on one interesting one were revealed in the purchase of a company called Lotus Tissue Repair by... |
f8e8627eb6a2f50ebe4bc9b2d256deee | https://www.forbes.com/sites/matthewherper/2013/05/03/the-plan-b-controversy-actually-we-do-let-kids-make-some-medical-decisions/ | The Plan B Absurdity: Emergency Contraception Is Treated Like A Drug That Could Be Abused | The Plan B Absurdity: Emergency Contraception Is Treated Like A Drug That Could Be Abused
(Credit: Dmitry Kalinovsky)
One of the main objections I've heard against expanding over-the-counter access to Plan B, the morning after pill, is expressed here by Penny Nance, CEO and President of Concerned Women for America (CWA... |
c95b1d0a8ae8ed53519bc65fb5296445 | https://www.forbes.com/sites/matthewherper/2013/05/08/why-psychiatrys-seismic-shift-will-happen-slowly/ | Why Psychiatry's Seismic Shift Will Happen Slowly | Why Psychiatry's Seismic Shift Will Happen Slowly
Thomas R. Insel, Director, National Institute of Mental Health. (Photo credit: Wikipedia)
Last week, Thomas Insel, Director of the National Institute of Mental Health, published a blog post that outlined a new approach for deciding what psychiatry research the U.S. gove... |
cb1a74d1d37b917b0e158dad704ee915 | https://www.forbes.com/sites/matthewherper/2013/05/23/glaxo-alleges-errors-in-nissens-critique-of-fdas-handling-of-avandia/ | Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia | Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia
This morning, I published a guest post from Steven Nissen, Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, alleging that the most likely rationale for an upcoming panel meeting being held by the Food and Drug Administr... |
8ad6a00b260f821862d89c562191d3a1 | https://www.forbes.com/sites/matthewherper/2013/05/23/steven-nissen-the-hidden-agenda-behind-the-fdas-avandia-hearings/ | Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings | Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings
Steven E. Nissen
This post was written by Steven E. Nissen MD, the Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. This commentary expresses his personal opinions and not necessarily the views of the Cleveland Clinic.
... |
790c70e4044777beaba028b79718253c | https://www.forbes.com/sites/matthewherper/2013/05/23/the-fda-responds-to-steve-nissens-criticism-of-upcoming-avandia-meeting/ | The FDA Responds To Steve Nissen's Criticism Of Upcoming Avandia Meeting | The FDA Responds To Steve Nissen's Criticism Of Upcoming Avandia Meeting
This morning, I published a guest post from Steven Nissen, Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, alleging that the most likely rationale for an upcoming panel meeting being held by the Food and Drug Adminis... |
afe20ff88bcc78b1b22a3dbf63618328 | https://www.forbes.com/sites/matthewherper/2013/07/14/the-best-and-worst-performing-biotech-stocks-july-5-to-july-12/?partner=yahootix | The Best- And Worst-Performing Biotech Stocks July 5 To July 12 | The Best- And Worst-Performing Biotech Stocks July 5 To July 12
These are the best and worst-performing medical and biotech stocks from July 5, 2013, to July 12, 2013. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had marke... |
9389f191462e96545ebbc226a43335ff | https://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/ | The Cost Of Creating A New Drug Now $5 Billion, Pushing Big Pharma To Change | The Cost Of Creating A New Drug Now $5 Billion, Pushing Big Pharma To Change
Susan Desmond-Hellmann
There's one factor that, as much as anything else, determines how many medicines are invented, what diseases they treat, and, to an extent, what price patients must pay for them: the cost of inventing and developing a ne... |
bcbb1a744a448437309a5596ea45f75d | https://www.forbes.com/sites/matthewherper/2013/09/04/can-a-great-hospital-save-a-city/ | City Surgeon: Can The Cleveland Clinic Save Its Hometown? | City Surgeon: Can The Cleveland Clinic Save Its Hometown?
Delos M. "Toby" Cosgrove
Delos M. "Toby" Cosgrove arrived at the Cleveland Clinic in 1975 as an "incredibly poor" 34-year-old dreaming of a life as a cardiac surgeon. "Heart surgery was the astronaut corps of health care," he says. He had $3,000 in his bank acco... |
b49f1874e3cec890e57786b0833f2c5a | https://www.forbes.com/sites/matthewherper/2013/12/26/the-most-important-new-drug-of-2013/ | The Most Important New Drug Of 2013 | The Most Important New Drug Of 2013
Gilead Sciences' Sovaldi, for hepatitis C, was the most important new medicine approved this year. It heralds the hope that a viral disease that afflicts more than 3 million Americans, can be treated with a few pills-- or even one – and that doctors and scientists may be able to dra... |
3362894df435410818cf8fa9d997e545 | https://www.forbes.com/sites/matthewherper/2014/02/28/the-market-for-dna-sequncing-based-down-syndrome-tests-could-exceed-6-billion/ | The Market For DNA-Sequencing-Based Down Syndrome Tests Could Exceed $6 Billion | The Market For DNA-Sequencing-Based Down Syndrome Tests Could Exceed $6 Billion
On Wednesday night the New England Journal of Medicine published a study showing that a new, DNA-sequencing based blood test provides a dramatic improvement in accuracy at screening for Down syndrome and a second, deadly disorder. That coul... |
93d2e4760a272e259c2565b17b8a475d | https://www.forbes.com/sites/matthewherper/2014/04/16/a-lucky-drug-made-pharmacyclics-robert-duggan-a-billionaire-will-long-term-success-follow/ | A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow? | A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow?
Robert Duggan was enjoying just your average Tampa vacation--a visit to the headquarters of the Church of Scientology, to which he's a major donor, and a double date with one of the world's top supermodels--when a board member ... |
d8ff0930cad8ad8d87026dc342ed45d3 | https://www.forbes.com/sites/matthewherper/2014/10/25/a-defense-of-the-ebola-quarantine/ | A Defense Of The Ebola Quarantine | A Defense Of The Ebola Quarantine
When Andrew Cuomo and Chris Christie, the governors of New York and New Jersey, announced that they would be putting in place an enforced quarantine when medical workers who had contact with Ebola in Liberia, Sierra Leone, or Guinea enter the United States, my immediate reaction was th... |
5833dacb7136dae1ddaaceddaea6f6f2 | https://www.forbes.com/sites/matthewherper/2014/11/03/rothberg-returns-with-star-trek-like-medical-device-to-create-images-and-cut-with-sound-waves/ | Rothberg Returns With Star Trek-Like Medical Device To Create Images And Cut With Sound Waves | Rothberg Returns With Star Trek-Like Medical Device To Create Images And Cut With Sound Waves
When we last left Jonathan Rothberg, the entrepreneur who first throttled DNA sequencing onto its Moore’s Law-beating path, he was leaving behind his genetics work in the tangle of Thermo Fisher’s $14 billion purchase of Li... |
8024ce6518ffec57e597407984c16c2f | https://www.forbes.com/sites/matthewherper/2014/11/17/after-years-under-attack-mercks-vytorin-proves-effective/ | After Years Under Attack, Merck's Vytorin Proves Effective | After Years Under Attack, Merck's Vytorin Proves Effective
Since 2007, the blockbuster cholesterol pills Zetia and Vytorin have been under a cloud as many doctors questioned their effectiveness at preventing heart attacks – and those questions have caused prescriptions of the pills to fall by more than 50%. Today, that... |
1b7030f105f87c8e5c26837d1a168eb2 | https://www.forbes.com/sites/matthewherper/2014/12/19/juno-shares-exploded-post-ipo-should-you-consider-buying-them/ | Juno Shares Exploded Post-IPO. Should You Consider Buying Them? | Juno Shares Exploded Post-IPO. Should You Consider Buying Them?
One of the most exciting companies in biotech just had one of the year’s most exciting initial public offerings.
Shares of Seattle-based Juno Therapeutics increased 60% from their listing price to $38 in late morning trading in the biggest biotech IPO of t... |
96ebf7d029f8dad02801bbd9ef9a3a41 | https://www.forbes.com/sites/matthewherper/2014/12/29/why-less-is-more-getting-better-outcomes-from-simpler-medication-regimens-for-complex-patients/ | Why Less is More: Getting Better Outcomes from Simpler Medication Regimens for Complex Patients | Why Less is More: Getting Better Outcomes from Simpler Medication Regimens for Complex Patients
A large body of research shows that a young and healthy adult’s working memory has the capacity to store between three and five “chunks” of information. Think about how you recall a phone number; most people use three chunk... |
4e822e4010e8176cde0c2858a7beb22c | https://www.forbes.com/sites/matthewherper/2015/01/05/30-under-30-the-entrepreneurs-making-healthcare-digital/ | 30 Under 30: The Entrepreneurs Making Healthcare Digital | 30 Under 30: The Entrepreneurs Making Healthcare Digital
Gallery: 2015 30 Under 30: Healthcare 31 images View gallery
Our annual list of the best-and-brightest in healthcare and science was so dense that we decided it was time for a spin-out.
This year there are two lists: this one, for entrepreneurs who ... |
d2a9cb2e8e43572d63325ee45e1abeff | https://www.forbes.com/sites/matthewherper/2015/01/06/surprise-with-60-million-genentech-deal-23andme-has-a-business-plan/ | Surprise! With $60 Million Genentech Deal, 23andMe Has A Business Plan | Surprise! With $60 Million Genentech Deal, 23andMe Has A Business Plan
This is more like it.
A deal being announced today with Genentech points the way for 23andMe, the personal genetics company backed by Facebook billionaire Yuri Milner and Google Ventures to become a sustainable business – even if the company’s discu... |
def33965020c2bf9e82daaa70d518384 | https://www.forbes.com/sites/matthewherper/2015/01/12/roche-spends-1-03-billion-for-majority-stake-in-cancer-genomics-firm/ | Roche Spends $1.03 Billion For Majority Stake In Foundation Medicine | Roche Spends $1.03 Billion For Majority Stake In Foundation Medicine
Roche, the world's largest maker of cancer drugs, is spending $1.03 billion to buy a 56.3% stake in Cambridge, Mass.-based Foundation Medicine, a company that uses genetics to help select drugs for cancer patients. Roche, based in Basel, Switzerland, ... |
6216e627907199775da5a6d957a2e53b | https://www.forbes.com/sites/matthewherper/2015/01/15/lawsuit-says-billionaires-health-venture-is-fraudulent-and-could-harm-patients/ | Whistleblower Lawsuit Calls Billionaire Patrick Soon-Shiong's Healthcare Startup 'Fraudulent' And Dangerous | Whistleblower Lawsuit Calls Billionaire Patrick Soon-Shiong's Healthcare Startup 'Fraudulent' And Dangerous
On the television newsmagazine “60 Minutes” and in a cover story for Forbes, Patrick Soon-Shiong, the world’s richest doctor, has promised that his new company, NantHealth, can dramatically improve care for cance... |
a6a99222c15ef7a94356bd911802f592 | https://www.forbes.com/sites/matthewherper/2015/02/11/neuroscience-treatments-to-watch/ | Neuroscience Treatments To Watch | Neuroscience Treatments To Watch
This article is a companion piece to Brain Boom: The Drug Companies Bringing Neuroscience Back From The Brink. Breakthroughs in genetics and sheer stubbornness on the part of drug developers could soon lead to new drugs for intractable brain diseases. Here's a look at what's happening ... |
eda07b2951a4bb16d6b45944b558fdb4 | https://www.forbes.com/sites/matthewherper/2015/03/31/what-i-hope-everyone-learns-from-pbs-big-cancer-documentary/ | What I Hope Everyone Learns From PBS' Big Cancer Documentary | What I Hope Everyone Learns From PBS' Big Cancer Documentary
No surprise: PBS’ “Cancer: The Emperor of All Maladies” is exactly the documentary one wishes every person who has ever been captivated by a breathless news report about cancer research would watch first. No surprise, because the book, by oncologist and resea... |
011b19fe363915dd32dde9348b20a39a | https://www.forbes.com/sites/matthewherper/2015/05/07/how-fake-news-articles-and-lies-about-billionaires-were-used-to-market-an-iffy-dietary-supplement/ | How Fake News Articles And Lies About Billionaires Were Used To Market An Iffy Dietary Supplement | How Fake News Articles And Lies About Billionaires Were Used To Market An Iffy Dietary Supplement
You’d be forgiven for thinking it was a Forbes story about a revolutionary new product. After all, the Forbes logo was there, Forbes was in the URL – ForbesMemoryPlus dot com – and the punchy writing described a breakthrou... |
07234651edc2d911b6b1afbbae8e6991 | https://www.forbes.com/sites/matthewherper/2015/05/07/prescription-fish-oil-maker-hires-top-lawyer-to-sue-fda-on-first-amendment-grounds/ | Prescription Fish Oil Maker Hires Top Lawyer To Sue FDA On First Amendment Grounds | Prescription Fish Oil Maker Hires Top Lawyer To Sue FDA On First Amendment Grounds
Amarin Pharmaceuticals, which was rebuffed by the Food and Drug Administration in its effort to market its fish oil pill Vascepa to treat high triglycerides, is suing the agency, saying its First Amendment rights are being violated.
To m... |
e4da9e35100ce27462dc8fe15367b1a3 | https://www.forbes.com/sites/matthewherper/2015/05/14/former-genentech-researchers-raise-217-million-for-company-to-fight-alzheimers-and-parkinsons/ | Genentech Brain Trust Leaves With $217 Million For New Startup To Fight Alzheimer's And Parkinson's | Genentech Brain Trust Leaves With $217 Million For New Startup To Fight Alzheimer's And Parkinson's
Marc Tessier-Lavigne
Three former top researchers at Genentech , the legendary biotech that is now part of Roche Holding , have raised $217 million in venture capital to start a new company, Denali Therapeutics, f... |
41d292eaa897982cb4ece18625c723bc | https://www.forbes.com/sites/matthewherper/2015/06/09/promising-result-in-postpartum-depression-creates-hope-for-inventing-new-psychiatric-drugs/ | Severe Depression Vanished In Four New Mothers After They Took This Drug. Is It For Real? | Severe Depression Vanished In Four New Mothers After They Took This Drug. Is It For Real?
In the months after their children were born, all four women plunged into severe, debilitating sadness. Antidepressant treatments didn’t work. They were admitted to the hospital. The women’s average score on a questionnaire called... |
5e82a1069239a389917e0d3f1b4d7a3e | https://www.forbes.com/sites/matthewherper/2015/08/10/bill-gates-and-13-other-investors-pour-120-million-into-revolutionary-gene-editing-startup/ | Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup | Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
Four years ago, the protein called CRISPR-Cas9, an enzyme that bacteria use to attack viruses that infect them, was unknown to humans. Now it is ubiquitous in science labs as the most efficient way of cutting-and-pasting DNA yet... |
d2dfb4aeef5f7603e06b407599929249 | https://www.forbes.com/sites/matthewherper/2015/08/17/patient-death-does-not-augur-doom-but-kite-pharma-needs-to-shut-its-big-mouth/ | Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth | Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth
This morning Kite Pharma confirmed that a patient had died in a trial of its cell therapy for a form of blood cancer. Market rumors about the death had pushed the company’s stock down 16% on Friday.
The stock has recovered most of its losse... |
ca49c2285cad3e210cb4b48230045b52 | https://www.forbes.com/sites/matthewherper/2015/10/12/eli-lillys-good-cholesterol-drug-goes-bad/?utm_source=followingimmediate&utm_medium=email&utm_campaign=20151012 | Eli Lilly's Good Cholesterol Drug Went Bad. Here's What That Means For Pharma | Eli Lilly's Good Cholesterol Drug Went Bad. Here's What That Means For Pharma
Albert Einstein never said that the definition of insanity is doing the same thing over and over again and expecting a different result. But whoever did say it was probably talking about a pharmaceutical executive.
This morning, Eli Lilly ... |
3410d0a6d8d17542937d4cb8860c45ca | https://www.forbes.com/sites/matthewherper/2015/10/21/23andmes-triumph-and-the-long-road-ahead/ | 23andMe's Triumph -- And The Long Road Ahead | 23andMe's Triumph -- And The Long Road Ahead
This morning 23andMe announced that it’s back, once again offering direct-to-consumer genetic tests from which consumers will draw health conclusions. This time it has the approval of the Food and Drug Administration.
It was a long road – appropriately, the FDA told 23andMe ... |
82052f3de749a064c3b1ae5a2fdaaeeb | https://www.forbes.com/sites/matthewherper/2016/02/04/here-are-some-solutions-to-the-martin-shkreli-problem/ | After The Martin Shkreli Circus, How Can We Fix Drug Pricing? | After The Martin Shkreli Circus, How Can We Fix Drug Pricing?
Martin Shkreli listens during a hearing of the House Oversight and Government Reform Committee on... [+] Capitol Hill February 4, 2016 in Washington, DC. (BRENDAN SMIALOWSKI/AFP/Getty Images)
There was no doubt that hauling Martin Shkreli, the infamous young... |
2f07115fbf3a1a9478023d06df60e891 | https://www.forbes.com/sites/matthewherper/2016/03/23/biotech-roars-back-on-forbes-list-of-the-top-venture-capitalists/ | Biotech Roars Back On Forbes' List Of The Top Venture Capitalists | Biotech Roars Back On Forbes' List Of The Top Venture Capitalists
Gallery: Top Biotech Investors On The 2016 Midas List 7 images View gallery
For years, venture capitalists who bet the seed money used to start small biotechnology companies have played second fiddle to their colleagues in the tech world, w... |
76cb283c2371d75f6d4558465f211fe7 | https://www.forbes.com/sites/matthewherper/2016/03/24/bio-maverick-craig-venter-hacks-bacteria-to-have-tiniest-possible-genetic-code/ | After 20 Year Quest, Biologists Create Synthetic Bacteria With No Extra Genes | After 20 Year Quest, Biologists Create Synthetic Bacteria With No Extra Genes
A team lead by the biologist J. Craig Venter has created, in the laboratory, a species of bacteria with a genetic code smaller than any known to exist in nature–basically creating a new organism with a minimal code necessary for life.
“The go... |
3cbe9c9c016407ea579968522d61967b | https://www.forbes.com/sites/matthewherper/2016/04/01/regenerons-drug-to-ease-terrible-rash-could-be-4-bilion-seller/ | Regeneron's Eczema Data Look Great. Don't Believe Me? Ask A Patient | Regeneron's Eczema Data Look Great. Don't Believe Me? Ask A Patient
Austin Jacobson, a 54-year-old trial attorney, had had rashes since he was a baby. At first they occurred in the warm weather when he played, and would go away with calamine lotion. But after he got married, and then had a child, they got worse. For tw... |
4cd2bd974dd246e253495cd3c580abef | https://www.forbes.com/sites/matthewherper/2016/06/05/abbvies-new-lung-cancer-drug-may-extend-patients-lives-but-could-disappoint-investors/ | AbbVie's New Lung Cancer Drug May Extend Patients' Lives, But Could Disappoint Investors | AbbVie's New Lung Cancer Drug May Extend Patients' Lives, But Could Disappoint Investors
An experimental drug may be the first medicine to make a real difference for patients with small cell lung cancer, a particularly deadly tumor that kills 60,000 Americans a year, according to new data presented here at the annual m... |
f83d1551a9063ed39612c0b52d0d03a3 | https://www.forbes.com/sites/matthewherper/2016/06/21/team-funded-by-billionaire-sean-parker-aims-to-be-first-to-use-crispr-gene-editing-in-people/ | Team Funded By Billionaire Sean Parker Aims To Be First To Use CRISPR Gene Editing In People | Team Funded By Billionaire Sean Parker Aims To Be First To Use CRISPR Gene Editing In People
Today at 10:40 a.m. Eastern Time, researchers from the University of Pennsylvania will ask a government panel for permission to be the first to use CRISPR, a new type of genetic engineering, to treat a disease in people.
The ef... |
e222d3ee37b9fb53b82a4361d8651607 | https://www.forbes.com/sites/matthewherper/2016/07/07/juno-therapeutics-stops-trial-of-cancer-killing-cells-after-3-patient-deaths/ | Juno Therapeutics Stops Trial Of Cancer-Killing Cells After 3 Patient Deaths | Juno Therapeutics Stops Trial Of Cancer-Killing Cells After 3 Patient Deaths
Three patients have died in a closely watched study of using genetically engineered white blood cells to treat adult leukemia patients, forcing the trial to be put on hold.
The news is a blow for Juno Therapeutics, the biotechnology startup va... |
8c96d06ad6150c351fba15b78d34562c | https://www.forbes.com/sites/matthewherper/2016/07/12/experimental-drug-dramatically-reduces-post-partum-depression-in-small-study/ | Experimental Drug Eliminates Postpartum Depression In 7 Of 10 Patients | Experimental Drug Eliminates Postpartum Depression In 7 Of 10 Patients
An experimental drug led to remission of postpartum depression in 7 of 10 patients, compared to 1 of 11 patients in a placebo group, boosting hope that the medicine might help women who become so distraught after childbirth that they need to be hosp... |
46e782750e08cbc25299d3c4b74e9550 | https://www.forbes.com/sites/matthewherper/2016/09/20/approving-a-muscular-dystrophy-drug-ignites-civil-war-at-the-fda/ | Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA | Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA
Yesterday, the Food and Drug Administration made history, approving a drug to treat Duchenne muscular dystrophy that works by targeting the genetic mutation at the root of the disease.
The decision was unique for reasons that were not just scientific. J... |
b188d12029ccc7a9d5e5a48b6f53345a | https://www.forbes.com/sites/matthewherper/2016/10/04/death-kickbacks-and-a-billionaire-the-story-of-a-dangerous-opioid/ | An Opioid Spray Showered Billionaire John Kapoor In Riches. Now He's Feeling The Pain | An Opioid Spray Showered Billionaire John Kapoor In Riches. Now He's Feeling The Pain
By Matthew Herper and Michela Tindera
On Mar. 25, 2016 Sarah Fuller, 32, was supposed to drop her mother's car at the shop. Her mom called at 8 a.m. to make sure her daughter was up. She got Sarah's fiancé. He found Sarah in her room,... |
1759fc0426febdf3772cdc6c143f101c | https://www.forbes.com/sites/matthewherper/2016/10/26/epipen-competitor-auvi-q-to-return-to-market-promising-lower-costs-for-patients/ | EpiPen Competitor Auvi-Q To Return To Market, Promising Lower Costs For Patients | EpiPen Competitor Auvi-Q To Return To Market, Promising Lower Costs For Patients
Eric and Evan Edwards, the twin brothers who invented the Auvi-Q device. (Image via Kaleo)
The main competitor to the EpiPen will be sold again in the first half of next year, its maker says. Like EpiPen, the shot, called Auvi-Q, can deliv... |
9242c82b8de95e652d372c53df281432 | https://www.forbes.com/sites/matthewherper/2016/12/14/should-big-data-pick-your-next-doctor/ | Should Big Data Pick Your Next Doctor? | Should Big Data Pick Your Next Doctor?
Grand Rounds CEO and co-founder Owen Tripp. Credit: Tim Pannell for Forbes.
This past spring, Owen Tripp, 37, was living the Silicon Valley dream. His latest company, Grand Rounds, had raised $100 million at a valuation said to be about $1 billion. He and his wife had a new baby, ... |
e4f50d50509099c0804f9d0f0426a035 | https://www.forbes.com/sites/matthewherper/2017/01/06/declaring-war-on-germs-with-bill-gates-and-a-veteran-ceo/ | Leaving Biogen, CEO Scangos To Head New Firm That Battles Germs | Leaving Biogen, CEO Scangos To Head New Firm That Battles Germs
Most drug companies are retreating from the business of creating drugs against viruses and, especially, bacteria. But a well-funded startup being announced today is taking the challenge head-on.
The new company, called Vir Biotechnology, will be lead by Ge... |
3261872880ed84716479dd3adbb517f3 | https://www.forbes.com/sites/matthewherper/2017/01/09/illumina-adds-ibm-watson-to-dna-test-for-cancer-patients/ | Illumina Adds IBM Watson To DNA Test For Cancer Patients | Illumina Adds IBM Watson To DNA Test For Cancer Patients
(Photo by Ben Hider/Getty Images)
Illumina and IBM announced that they would be bundling IBM’s Watson Genomics product with Illumina’s TruSight Tumor 170, a tool used to help match very sick cancer patients with drugs that might help them.
The move is the latest ... |
36d1af93a9b0a42cc334799678c034af | https://www.forbes.com/sites/matthewherper/2017/01/09/illumina-promises-to-sequence-human-genome-for-100-but-not-quite-yet/?sh=60fa3abf386d | Illumina Promises To Sequence Human Genome For $100 -- But Not Quite Yet | Illumina Promises To Sequence Human Genome For $100 -- But Not Quite Yet
Illumina, the largest maker of DNA sequencers, is launching a new DNA sequencer with new architecture it says could push the cost of decoding a human genome from $1,000 to $100–although that decrease will not come for years.
“This is good news, af... |
2d00416e2c1a094b48743ccfd2a2bfcd | https://www.forbes.com/sites/matthewherper/2017/01/19/epipen-competitor-auvi-q-to-be-free-for-most-patients-but-cost-4500-for-insurers-in-rube-goldberg-scheme/ | In Rube Goldberg Price Scheme, EpiPen Competitor Auvi-Q To Be Free For Patients, $4,500 For Their Insurers | In Rube Goldberg Price Scheme, EpiPen Competitor Auvi-Q To Be Free For Patients, $4,500 For Their Insurers
Auvi-Q, the main competitor to EpiPen, is announcing a convoluted pricing strategy try to make sure patients will be able to get access to its injection for treating life-threatening allergic reactions.
Kaleo, Auv... |
fece87cae09228e7887fb397022bba8f | https://www.forbes.com/sites/matthewherper/2017/02/10/a-6000-price-hike-should-give-drug-companies-a-disgusting-sense-of-deja-vu/?sh=317c910971f5 | Why Did That Drug Price Increase 6,000%? It's The Law | Why Did That Drug Price Increase 6,000%? It's The Law
Groundhog Day, anyone? (Photo by Andrew Burton/Getty Images)
It’s happened again. Of course it has happened again. A drug company has brought a drug that has been available as a generic elsewhere in the world for decades at a shockingly inflated price.
The drug, in ... |
aab4ca6dc582ee2291815085df213eb4 | https://www.forbes.com/sites/matthewherper/2017/03/07/15-million-people-could-lose-health-insurance-under-the-gops-obamacare-replacement/ | 15 Million Fewer People Might Have Health Insurance Under The GOP's Obamacare Replacement | 15 Million Fewer People Might Have Health Insurance Under The GOP's Obamacare Replacement
Donald Trump waves after speaking as Vice President Mike Pence and U.S. House Speaker Paul Ryan... [+] applaud during a joint session of Congress in Washington, D.C., on Feb. 28, 2017. Photographer: Andrew Harrer/Bloomberg
Last ni... |
41944dcac44c751d40112a5709313ef3 | https://www.forbes.com/sites/matthewherper/2017/04/03/for-bristol-myers-cancer-drug-a-victory-and-a-mystery/ | For Bristol-Myers, A Victory And A Mystery | For Bristol-Myers, A Victory And A Mystery
New data presented at a medical conference show that combining Bristol-Myers Squibb’s two immune-boosting cancer drug appears to extend the lives of melanoma patients longer than using either alone.
But a big question lingers about one of the drugs, Opdivo: why did it fail to ... |
6360a3e2358db1dba9f3cefb5ec638e0 | https://www.forbes.com/sites/matthewherper/2017/07/05/to-gag-a-shkreli/ | To Gag A Shkreli | To Gag A Shkreli
It’s all the journalists’ fault that Martin Shkreli is talking, his lawyer insisted this morning. The lawyer, Benjamin Brafman, told a judge that “certain representatives of the press” have gone out of their way to “bait” Shkreli into making public statements.
This seems like a strange claim, given tha... |
a0c1e601fd6effa02890ee887faa4cb6 | https://www.forbes.com/sites/matthewherper/2017/08/09/biotech-wunderkind-raises-1-1-billion-to-fund-pharma-startups/ | Biotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups | Biotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups
Vivek Ramaswamy, a former hedge fund partner who went on to engineer one of the biggest biotech initial public offerings in history, has a new source of cash: his investment vehicle, Roivant Sciences, just raised $1.1 billion from investors including the So... |
e5a3ad27b8c479aeb04efe63710c3e5c | https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/ | The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad | The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad
A group of white elephants trumpet. ( ROBERTO SCHMIDT/AFP/Getty Images)
It was six men of Indostan, to learning much inclined, who went to see the elephant (Though all of them were blind), that each by observation, might satisfy his... |
b7987c9768f1e21f47e91dd038ab2a8f | https://www.forbes.com/sites/matthewherper/2017/11/09/new-drug-eases-postpartum-depression-in-victory-for-tiny-sage-therapeutics/ | New Drug Eases Postpartum Depression In Victory For Tiny Sage Therapeutics | New Drug Eases Postpartum Depression In Victory For Tiny Sage Therapeutics
An experimental drug improved symptoms of post-partum depression within a matter of days in a hard-won victory for antidepressant drug development.
It is, of course, also a big win for Sage Therapeutics, the Cambridge, Mass.-based biotechnology ... |
64eafb537388122b581344489cc3501c | https://www.forbes.com/sites/matthewherper/2017/12/05/big-datas-top-breast-cancer-oncologists/ | 27 Top Breast Cancer Oncologists, Picked By Big Data | 27 Top Breast Cancer Oncologists, Picked By Big Data
What's below is the result of a challenge: can a company that helps patients find the right doctor identify the best physicians over all, or at least come close? (You can also go here for a list of top cardiologists.)
Last year, I wrote a magazine profile of a compan... |
0437065d5751c30f5d4a7af34e11e295 | https://www.forbes.com/sites/matthewherper/2017/12/28/mourning-ben-barres-the-transgender-scientist-who-changed-neuroscience/ | Mourning Ben Barres, The Transgender Scientist Who Changed Neuroscience | Mourning Ben Barres, The Transgender Scientist Who Changed Neuroscience
Ben Barres, a neurobiologist at Stanford University's Medical Center, puts on a lab coat in his lab... [+] in the university's campus. (Photo/Marcio Jose Sanchez)
Ben Barres, a neuroscientist who established the importance of glial cells, which com... |
c27bc0cd3009b64cdbf7c9b3b3b3ffe5 | https://www.forbes.com/sites/matthewherper/2018/01/08/illumina-unveils-20000-desktop-sequencer-aimed-at-sequencing-germs/ | Illumina Unveils $20,000 Desktop Sequencer Aimed At Sequencing Germs | Illumina Unveils $20,000 Desktop Sequencer Aimed At Sequencing Germs
Illumina's new $20,000 iSeq 100 DNA sequencer. Illumina
Illumina, the dominant maker of DNA sequencers that are used in drug discovery, medicine, and biological research, is unveiling a new toy: A $19,900, one-cubic-foot box that puts DNA sequencing i... |
d9d2350486250b9e4514f597b3d5a5b9 | https://www.forbes.com/sites/matthewherper/2018/02/07/why-a-gene-therapy-pioneer-is-raising-concerns-about-treatments-he-championed/ | Why A Gene Therapy Pioneer Is Raising Concerns About Treatments He Championed | Why A Gene Therapy Pioneer Is Raising Concerns About Treatments He Championed
James Wilson, gene therapy pioneer Jim Wilson
Jim Wilson has been one of gene therapy's pioneers. Now he's raising concerns about the safety of a technology he helped develop – at least when it is pushed to its limits. In two new studies his ... |
62f0c66d5d082b86afd2c154e757f109 | https://www.forbes.com/sites/matthewherper/2018/03/26/ai-telemedicine-quantum-new-novartis-boss-says-tech-will-finally-change-the-drug-biz/?sh=27f788d56b54 | AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz | AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz
Global Head Drug Development and Chief Medical of Swiss multinational pharmaceutical company... [+] Novartis, Vasant Narasimhan. (AP Photo/Thibault Camus, Pool)
What does the youngest chief executive in Big Pharma want? A control ro... |
a1c9d5ea40550db94bd620e440b2c7a8 | https://www.forbes.com/sites/matthewherper/2018/05/23/freenome-sets-sights-on-blood-test-to-detect-colon-cancer/ | Freenome Sets Sights On Blood Test To Detect Colon Cancer | Freenome Sets Sights On Blood Test To Detect Colon Cancer
Freenome chief executive Gabriel Otte Freenome
Freenome, a Silicon Valley startup aiming to develop blood tests to detect cancer early, is choosing its first product: a test to detect colon cancer.
The company was founded by Chief Executive Gabriel Otte and Chie... |
75f03f66b85b8e1ab1c73efc92f92abf | https://www.forbes.com/sites/matthewherper/2018/09/20/for-a-new-device-to-treat-maternal-bleeding-a-young-entrepreneurs-big-step-was-letting-go/ | For A New Device To Treat Maternal Bleeding, A Young Entrepreneur's Big Step Was Passing The Torch | For A New Device To Treat Maternal Bleeding, A Young Entrepreneur's Big Step Was Passing The Torch
Jessie Becker co-founded Alydia Health in 2011. Alydia Health
This morning, Alydia Health, a tiny Menlo Park, California, startup cofounded by a 21-year-old woman, announced that it has secured $10 million in funding to t... |
564c6c2b6a012bc42a61ea8cc498ea1e | https://www.forbes.com/sites/matthewherper/2018/09/28/crispr-based-drugmaker-raises-80-million/ | CRISPR-Based Drugmaker Raises $80 Million | CRISPR-Based Drugmaker Raises $80 Million
DNA replication Getty
KSQ Therapeutics, a Cambridge, Massachusetts-based biotechnology company that uses the genetic-engineering tool CRISPR to develop new drugs, has raised $80 million, its second big fundraise in as many years. KSQ raised $76 million last October.
Instead of... |
e6f48ab19e345807ac6031993c96197b | https://www.forbes.com/sites/matthewherper/2018/11/20/is-amarins-fish-oil-derived-drug-a-historic-breakthrough-or-not-its-complicated/ | Is Amarin’s Fish-Oil-Derived Drug A Historic Breakthrough Or Not? It’s Complicated | Is Amarin’s Fish-Oil-Derived Drug A Historic Breakthrough Or Not? It’s Complicated
Vascepa is not just any fish oil, and is different from over-the-counter supplements. Here's a ... [+] picture of a salmon jumping over the Goldstream River. Getty
Cardiologists are still grappling with clinical trial results released l... |
be21e2506452f9bf947e52cd233a4542 | https://www.forbes.com/sites/matthewherper/2018/12/10/buzzy-startup-10x-genomics-buys-spatial-transcriptomics-in-bet-on-genetic-tools/ | Buzzy Startup 10x Genomics Buys Spatial Transcriptomics In Bet On Genetic Tools | Buzzy Startup 10x Genomics Buys Spatial Transcriptomics In Bet On Genetic Tools
10x Genomics Chief Executive Serge Saxonov: "“We generally understate how little biology we, the ... [+] world, know.” 10x Genomics
10x Genomics, a buzzy, closely held genetics startup based in Pleasanton, Calif., is purchasing Stockholm-b... |
0988264dc70018c328e9c44458216191 | https://www.forbes.com/sites/matthewherper/2018/12/17/fda-names-flatiron-health-executive-amy-abernethy-deputy-commissioner/ | FDA Names Flatiron Health Executive Amy Abernethy Deputy Commissioner | FDA Names Flatiron Health Executive Amy Abernethy Deputy Commissioner
Amy Abernethy, chief medical officer of Flatiron Health, sits with Robert Califf, at a company event ... [+] early this year. Flatiron Health
The Food and Drug Administration has named Amy Abernethy, currently the chief medical officer at Flatiron H... |
be75af0fc0a16184535b4dd50668df0c | https://www.forbes.com/sites/matthewherper/2018/12/21/what-can-you-do-for-your-loved-ones-when-youre-dying-of-cancer/ | What Can You Do For Your Loved Ones When You’re Dying Of Cancer? | What Can You Do For Your Loved Ones When You’re Dying Of Cancer?
“Just remember data always has a face.”
That was the advice that Michael Becker, a former biotechnology company chief executive who now has head and neck cancer, told the assembled executives at the Forbes Healthcare Summit in New York last month. Behind ... |
cc8a4240acddc04765cc17d1d0cc0d4d | https://www.forbes.com/sites/matthewhulbert/2012/09/29/president-putins-growing-gas-insanity/ | President Putin's Growing Gas Insanity | President Putin's Growing Gas Insanity
Einstein once said the definition of insanity ‘is doing the same thing over and over again, and expecting a different outcome’. By most counts, that makes Gazprom and President Putin, pretty insane. They’ve spent the last decade trying to sell gas into China, and repeatedly failin... |
b1a6580b2be0ac2bc404d29ef5a1b41e | https://www.forbes.com/sites/matthewhulbert/2012/11/26/gazprom-takes-southern-corridor-spoils/ | Gazprom Tightens Control Over European Supply | Gazprom Tightens Control Over European Supply
English: Gazprom Headquarters in Moscow
Well, it’s finally coming; Russia is starting construction of the €16bn South Stream pipeline on 7th December to make sure it retains a strong grip over South East European and Central & Eastern European gas supplies. But whether this... |
697aff0dc68574e5e1ed3ab063a0814e | https://www.forbes.com/sites/matthewjcooper/2020/04/01/tiger-woods-phil-mickelson-match-to-include-brady-and-manning/ | Tiger Woods, Phil Mickelson Match Rumored To Include Brady And Manning | Tiger Woods, Phil Mickelson Match Rumored To Include Brady And Manning
Phil Mickelson and Tiger Woods will have to enforce social distancing if they conduct a repeat of ... [+] The Match. (Photo by Harry How/Getty Images for The Match) Getty Images for The Match
A repeat of 2018’s showdown between Tiger Woods and Phil... |
2c5a0fa04991582f58d94136de09ebd3 | https://www.forbes.com/sites/matthewkorda/2020/08/12/democrats-and-republicans-agree-phase-out-land-based-nuclear-missiles/?sh=2a6fa698109d | Democrats And Republicans Agree: Phase Out Land-Based Nuclear Missiles | Democrats And Republicans Agree: Phase Out Land-Based Nuclear Missiles
Although Democrats and Republicans increasingly seem worlds apart, when it comes to nuclear weapons issues, they’re actually much closer than one might think.
According to a new report by the Program for Public Consultation at the University of Mary... |
425f0855e3db5a8cfd8744af9da53bdc | https://www.forbes.com/sites/matthewnewton/2011/09/30/resurrecting-the-deleted-city-of-the-internets-early-pioneers/ | Resurrecting 'The Deleted City' Of The Internet's Early Pioneers | Resurrecting 'The Deleted City' Of The Internet's Early Pioneers
When the Internet was young, before Blogger, WordPress, and Movable Type enabled the public to easily publish volumes of information to the world, sites like GeoCities provided a free home. Like so many services that were free in the early days of the Int... |
356892951a04648e10c0edf401c62572 | https://www.forbes.com/sites/matthewstepp/2013/01/02/the-past-present-and-new-year-of-u-s-clean-energy-policy/ | The Past, Present, and New Year of U.S. Clean Energy Policy | The Past, Present, and New Year of U.S. Clean Energy Policy
When President Barack Obama was inaugurated on January 20, 2009, clean energy was largely a policymaking afterthought. Federal investment in clean energy research and development (R&D) stood at just over $4 billion a year - less than 40 percent of its peak in ... |
4c5a3e23b55ce7c4e4916aef1d9c706c | https://www.forbes.com/sites/matthewstibbe/2011/05/19/deadhead-flights/ | How to fly Private Jets at Airline Prices | How to fly Private Jets at Airline Prices
Image via Wikipedia
For the first class crowd, a private jet is the ultimate upgrade. But buying or chartering is too expensive for all but a few. So how do you get to fly on a business jet for business-class prices?
Fly empty sectors
The first option is to buy a seat on a 'dea... |
877b6a40e806d18578de9cbd0d42e0c3 | https://www.forbes.com/sites/matthewstibbe/2013/05/06/googles-shiny-new-82-million-airport-terminal-in-silicon-valley/ | Google's Shiny New $82 Million Airport Terminal In Silicon Valley | Google's Shiny New $82 Million Airport Terminal In Silicon Valley
Interior rendering for Google's new FBO in Silicon Valley. Source: San José International Airport
A few years ago I taxied past a hangar at San Carlos airport. The door was open to the immaculate interior and I could see an array of jets and aerobatic li... |
f191f00d2bfd2fffaa98eb06715fad03 | https://www.forbes.com/sites/matthickey/2013/09/12/hbos-cto-unattached-hbogo-is-a-no-go/ | HBO's CTO: Unattached HBOGo Is A No-Go | HBO's CTO: Unattached HBOGo Is A No-Go
SAN DIEGO, CA - JULY 19: Game of Thrones writers and cast members, still available only via cable,... [+] satellite, or piracy. (Image credit: Getty Images via @daylife) The big question is: will @hbogo be able to handle tonight’s traffic? Early signs point to no. #got... |
a19f6d09877dd055f65380f5fa95a409 | https://www.forbes.com/sites/matthickey/2014/04/11/amazons-comixology-acquisition-has-some-readers-concerned/ | Amazon's ComiXology Acquisition Has Some Readers Concerned | Amazon's ComiXology Acquisition Has Some Readers Concerned
Amazon yesterday announced that it would be acquiring ComiXology, a combo app and store for comic books on digital devices. Think of it as an iTunes for the Marvel and DC crowd.
The app is quite popular with tablet owners that consume comics. Anyone who’s ever ... |
7cb6c5143a7572a404c354bacab93a38 | https://www.forbes.com/sites/matthickey/2015/09/26/if-netflix-is-indeed-insourcing-tv-production-then-it-may-change-tv-forever/ | If Netflix Is Indeed Insourcing TV Production Then It May Change TV Forever | If Netflix Is Indeed Insourcing TV Production Then It May Change TV Forever
Apparently not content with using the traditional broadcast model of acquiring television shows for broadcast, Netflix is said to be doubling down into the business of producing its own shows in-house. And if the report from Bloomberg B... |
c472d814c38f0ea79e1b382f89d09521 | https://www.forbes.com/sites/matthickey/2015/10/31/facebook-testing-craigslist-threatening-marketplace-for-selling-to-online-friends/ | Facebook Testing Craigslist-Threatening Marketplace For Selling To Online Friends | Facebook Testing Craigslist-Threatening Marketplace For Selling To Online Friends
I’m cheap. Like, really cheap. I’m a journalist, we're supposed to be like that. Thus I do a lot of my shopping online, but Amazon doesn’t get all of my money. No, sometimes I like to keep it local, and I’ve had some great success finding... |
947be34aa6642f48b612017167e22387 | https://www.forbes.com/sites/matthickey/2016/05/17/with-an-80-million-budget-the-tetris-movie-youve-been-waiting-for-is-on-the-way/ | With An $80 Million Budget, The 'Tetris' Movie You've Been Waiting For Is On The Way | With An $80 Million Budget, The 'Tetris' Movie You've Been Waiting For Is On The Way
We’re not sure why, but a combined Chinese and American production studio has pressed start on a feature film based on the best-selling video game series Tetris.
Yes, the Russian Tetris, with the memorable music and falling blocks that... |
ef020248a4891bd1da10675edeb7168a | https://www.forbes.com/sites/matthougan/2018/05/23/what-golds-history-teaches-us-about-bitcoin-as-a-store-of-value/ | What Gold's History Teaches Us About Bitcoin As A Store Of Value | What Gold's History Teaches Us About Bitcoin As A Store Of Value
Shutterstock
The most compelling use case for Bitcoin today is as a store of value. But too often, people dismiss the idea because of Bitcoin’s volatility.
How can it be a store of value when its price moves 20% in a month?
It’s a refrain we’ve heard rece... |
7e69b9a13110598bd3cdc68ab21bc803 | https://www.forbes.com/sites/matthougan/2019/08/21/bitcoin-vs-gold-is-bitcoin-really-a-new-safe-haven-asset/ | Bitcoin vs. Gold: Is Bitcoin Really A New 'Safe Haven' Asset? | Bitcoin vs. Gold: Is Bitcoin Really A New 'Safe Haven' Asset?
Is bitcoin a new digital gold?
That’s the question on everyone’s mind recently.
Is bitcoin the new gold? Yes ... but it's gold circa 1973. (Photo by Ulrich Baumgarten via Getty ... [+] Images) U. Baumgarten via Getty Images
Over the weekend, Barron’s laid o... |
44c213ee4013e1cc739a309ca0ecd28d | https://www.forbes.com/sites/matthunckler/2015/05/08/collaboration-fuels-startup-community-in-north-carolinas-triangle/ | Collaboration Fuels Startup Community in North Carolina's Triangle | Collaboration Fuels Startup Community in North Carolina's Triangle
"The Triangle startup scene is rock n’ rolling," effused Steve Case, the AOL co-founder and renowned tech investor. "People are working together to help each other, help each company be successful, and help the area grow as a startup region."
On May... |
7b6341c45ce0572f13b444cedb68df3e | https://www.forbes.com/sites/matthunckler/2015/08/17/how-this-hackathon-is-inspiring-students-to-better-education/ | How This Hackathon Is Inspiring Students To Better Education | How This Hackathon Is Inspiring Students To Better Education
HackingEDU is inspiring college students to hack their way to a better educational future. The organization's inaugural Hackathon is coming up on October 23-25th at the San Mateo Event Center in San Francisco and is set to be the largest educational hackathon... |
be82c9ba8972b547bfe0f91277a03603 | https://www.forbes.com/sites/matthunckler/2016/05/17/is-neatso-the-uber-of-home-cleaning/ | Is Neatso The Uber Of Home Cleaning? | Is Neatso The Uber Of Home Cleaning?
Piggybacking on the growth of on-demand apps and a $15 billion home cleaning market, North Carolina startup Neatso wants to be the Uber of home cleaning. Driven by market need as well as a personal connection to the industry, Neatso hopes to penetrate the vibrant apartment market an... |
7151eca4e70afcb9340874a79cd36176 | https://www.forbes.com/sites/matthunckler/2017/02/20/emotional-intelligence-in-business-and-life/ | Emotional Intelligence: Your Secret Weapon For Success In Business And Life | Emotional Intelligence: Your Secret Weapon For Success In Business And Life
ashleyzahabian.com
Ashley Zahabian had never heard of emotional intelligence, or EQ for “emotional quotient,” before she was hospitalized for severe anorexia as a teenager. After her recovery, EQ became the cause that drove her and led her down... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.